Literature DB >> 18710860

Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice.

Bo Young Jeon1, Steven C Derrick, Jaehyun Lim, Kristopher Kolibab, Veerabadran Dheenadhayalan, Amy Li Yang, Barry Kreiswirth, Sheldon L Morris.   

Abstract

Recent preclinical and epidemiologic studies have suggested that certain Mycobacterium tuberculosis genotypes (in particular, Beijing lineage strains) may be resistant to Mycobacterium bovis BCG vaccine-induced antituberculosis protective immunity. To investigate the strain specificity of BCG-induced protective responses in a murine model of pulmonary tuberculosis, C57BL/6 mice were vaccinated with BCG vaccine and then challenged 2 months later with one of nine M. tuberculosis isolates. Four of these strains were from the W-Beijing lineage (HN878, N4, NHN5, and ChS) while four were non-Beijing-type isolates (C913, CDC1551, NY669, and NY920). As a control, the WHO standard M. tuberculosis Erdman strain was evaluated in these vaccination/challenge experiments. To assess the protective responses evoked by BCG immunization, organ bacterial burdens and lung pathology were assessed in vaccinated and naïve mice at 4, 12, and 20 weeks postchallenge as well as during the day of infection. At 4 weeks after the aerosol challenge with each of these strains, significantly reduced bacterial growth in the lungs and spleens and significantly improved lung pathology were seen in all vaccinated animals compared to naïve controls. After 12 weeks, reduced organ bacterial burdens were detected in vaccinated animals infected with six of nine challenge strains. Although lung CFU values were lower in vaccinated mice for only three of nine groups at 20 weeks postchallenge, significantly decreased lung inflammation was seen in all immunized animals relative to controls at 20 weeks postchallenge. Taken together, these data demonstrate that BCG vaccination protects against infection with diverse M. tuberculosis strains in the mouse model of pulmonary tuberculosis and suggest that strain-specific resistance to BCG-induced protective immunity may be uncommon.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18710860      PMCID: PMC2573355          DOI: 10.1128/IAI.00019-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

Review 1.  Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains.

Authors:  Pablo J Bifani; Barun Mathema; Natalia E Kurepina; Barry N Kreiswirth
Journal:  Trends Microbiol       Date:  2002-01       Impact factor: 17.079

2.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta.

Authors:  C Manca; L Tsenova; A Bergtold; S Freeman; M Tovey; J M Musser; C E Barry; V H Freedman; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  Development of variable-number tandem repeat typing of Mycobacterium bovis: comparison of results with those obtained by using existing exact tandem repeats and spoligotyping.

Authors:  Solvig Roring; Alistair Scott; David Brittain; Ian Walker; Glyn Hewinson; Sydney Neill; Robin Skuce
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.

Authors:  Giovanni Delogu; Amy Li; Charlene Repique; Frank Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature.

Authors:  T F Brewer
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

6.  Growth of a highly virulent strain of Mycobacterium tuberculosis in mice of differing susceptibility to tuberculous challenge.

Authors:  C L Kelley; F M Collins
Journal:  Tuber Lung Dis       Date:  1999

Review 7.  BCG: the challenge continues.

Authors:  P E Fine
Journal:  Scand J Infect Dis       Date:  2001

8.  Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model.

Authors:  Gopinath S Palanisamy; Erin E Smith; Crystal A Shanley; Diane J Ordway; Ian M Orme; Randall J Basaraba
Journal:  Tuberculosis (Edinb)       Date:  2008-03-05       Impact factor: 3.131

9.  DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge.

Authors:  Charlene J Repique; Amy Li; Frank M Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

10.  Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review.

Authors:  Judith R Glynn; Jennifer Whiteley; Pablo J Bifani; Kristin Kremer; Dick van Soolingen
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more
  43 in total

Review 1.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

2.  BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity.

Authors:  Andrew Keyser; Jolynn M Troudt; Jennifer L Taylor; Angelo A Izzo
Journal:  Vaccine       Date:  2011-10-18       Impact factor: 3.641

3.  Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Authors:  Diane J Ordway; Shaobin Shang; Marcela Henao-Tamayo; Andres Obregon-Henao; Laura Nold; Megan Caraway; Crystal A Shanley; Randall J Basaraba; Colleen G Duncan; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 4.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 5.  Diversity and evolution of Mycobacterium tuberculosis: moving to whole-genome-based approaches.

Authors:  Stefan Niemann; Philip Supply
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-04       Impact factor: 6.915

6.  Mycobacterium tuberculosis strains of the modern sublineage of the Beijing family are more likely to display increased virulence than strains of the ancient sublineage.

Authors:  Simone C M Ribeiro; Lia Lima Gomes; Eduardo P Amaral; Marcelle R M Andrade; Fabricio M Almeida; Andreza L Rezende; Verônica R Lanes; Eulógio C Q Carvalho; Philip N Suffys; Igor Mokrousov; Elena B Lasunskaia
Journal:  J Clin Microbiol       Date:  2014-05-14       Impact factor: 5.948

7.  Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice.

Authors:  Steven C Derrick; Kristopher Kolibab; Amy Yang; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2014-08-20

Review 8.  Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.

Authors:  Hansong Chae; Sung Jae Shin
Journal:  J Microbiol       Date:  2018-05-02       Impact factor: 3.422

9.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

10.  Mycobacterium tuberculosis transmission is not related to household genotype in a setting of high endemicity.

Authors:  B J Marais; A C Hesseling; H S Schaaf; R P Gie; P D van Helden; R M Warren
Journal:  J Clin Microbiol       Date:  2009-03-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.